返回 
加入收藏
重组人白介素-11治疗化疗引起的血小板减少症的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 重组人白介素-11治疗化疗引起的血小板减少症的临床观察 |
| TITLE： | |
| 摘要： | 目的：观察重组人白介素-11治疗由化疗引起的血小板减少症的临床疗效及安全性。方法：选取化疗引起的血小板减少症患者86例，按随机数字表法分为对照组和观察组，各43例。对照组患者输注血小板10 IU，2～3 d 1次；观察组患者给予注射用重组人白介素-11，25～50 μg/kg，qd。两组患者均治疗14 d。观察两组患者临床疗效及治疗前后血小板计数，并比较两组患者血小板减少持续与恢复时间，以及不良反应发生情况。结果：观察组患者临床总有效率为81.40％，显著高于对照组的62.79％，差异有统计学意义（P＜0.05）。两组患者治疗前血小板计数比较，差异无统计学意义（P＞0.05）；治疗后，两组患者血小板计数均显著升高，且观察组显著高于对照组，差异均有统计学意义（P＜0.05）。观察组患者血小板＜50×109 L－1持续时间，恢复至70×109 L－1和100×109 L－1时间均显著短于对照组，差异均有统计学意义（P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：重组人白介素-11治疗化疗引起的血小板减少症有较好的疗效，能明显改善患者血小板计数，缩短血小板减少持续与恢复时间，且安全性较好。 |
| ABSTRACT： | OBJECTIVE： To observe clinical efficacy and safety of recombinant human interleukin-11 （rhIL-11） in the treatment of chemotherapy-induced thrombocytopenia. METHODS： 86 patients with thrombocytopenia induced by chemotherapy were selected and divided into control group and observation group according to random number table， with 43 cases in each group. Control group was given platelet transfusion 10 IU， once every 2-3 d； observation group was given Recombinant human IL-11 for injection 25-50 μg/kg， qd. Both groups received treatment for 14 d. Clinical efficacies of 2 groups were observed as well as platelet count before and after treatment. The duration of platelet decrease and recovery， the occurrence of ADR were compared between 2 groups. RESULTS： The total effective rate of observation group was 81.40％， which was significantly higher than 62.79％ of control group， with statistical significance （P＜0.05）. There was no statistical significance in platelet count between 2 groups before treatment （P＞0.05）； after treatment， platelet count of 2 groups increased significantly， and the observation group was significantly higher than the control group， with statistical significance （P＜0.05）. The duration of platelet count ＜50×109 L－1， the time of platelet count recovering to 70×109 L－1 and 100×109 L－1 in observation group were significantly shorter than in control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. CONCLUSIONS： rhIL-11 shows good therapeutic efficacy in the treatment of chemotherapy-induced thrombocytopenia， and can significantly improve platelet count， shorten the duratione of platelet decrease and recovery with good safety. |
| 期刊： | 2016年第27卷第35期 |
| 作者： | 黄辉，章展，李建华，唐小万，陈莉莉 |
| AUTHORS： | HUANG Hui，ZHANG Zhan，LI Jianhua，TANG Xiaowan，CHEN Lili |
| 关键字： | 血小板减少症；重组人白介素-11；临床疗效；安全性 |
| KEYWORDS： | Thrombocytopenia； Recombinant human interleukin-11； Clinical efficacy； Safety |
| 阅读数： | 356 次 |
| 本月下载数： | 1 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
